Dendreon board of directors. Apr 17, 2012 · Dr.

Dendreon board of directors Dendreon employs 606 employees. Mitchell H. Oct 26, 2021 · Additionally, Kate McKinley, Chief Executive Officer of Elevar Therapeutics, Inc. Jun 27, 2023 · Her expertise will be instrumental in the successful development of our platforms, … Continue reading “A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors” With over 30 years of experience as a biotechnology leader, founder, and operator, Heidi is perfectly positioned to thrive in her role as A-Alpha Bio’s first independent board Apr 17, 2012 · Best Places to Work; Employer Resources; Post Jobs; Talent Solutions; Advertise; Submit a Press Release Dr. Previously, he served as president and chief executive officer of Dendreon since 2003, as Nov 8, 2011 · SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (Nasdaq: DNDN) today announced that Dennis M. Fenton has He has been redesignated from Non-Independent Non-Executive Director to Non-Independent Non-Executive Chairman, effective 7 January 2025. Explore {Dendreon's key management people. , effective April 1, 2024. The Dendreon management team includes William Amick (CEO, President) , Marcus Wright (Talent Acquisition Manager) , and Kevin Helmbacher (SVP of Legal and Compliance and General Counsel) . Stump joined our board of directors in September 2013. Mr. Gold currently serves as executive chairman of Dendreon Corporation's Board of Directors. Discover current leadership team members including founders, CEO, other executives and board directors. "Dennis brings a wealth of experience and knowledge from the 25 years he spent at Amgen, transforming the company from a small biotech to one of the world's leading biotechnology companies, and we welcome him to Dendreon's Board of Directors," said Richard B. " Bishop has held a range of executive positions in the pharmaceutical industry, including as COO at Dendreon, which launched the first cellular immunotherapy for prostate cancer. Jun 2, 2010 · "We welcome Dave to Dendreon's Board of Directors. Dendreon ushered in an entirely new era in cancer treatment with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010. She previously served as Chair of the Board Athersys, where she joined the board in November 2020, and also served as Chair of its Audit Committee. Gold and his team developed a new class of therapies called active cellular immunotherapy (ACI), designed to engage a patient’s own immune system against cancer. Dr. Age: 35 Previous jobs: Chief business officer, board director of Dendreon, May 2002 to present; Dendreon vice president of business development, June 2001 to May 2002; Vice president, business development, Data Critical, now a division of General Electric, April 2000 to May 2001; co-founder, president and CEO of Elixis Member Board of Directors (Director) at Dendreon. Johnson received his B. Johnson resigned from his role as the non-executive chairman of the Board of Directors for Autolus Therapeutics plc. Fenton has Aug 22, 2011 · SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (Nasdaq: DNDN) today announced that John H. Board expansion adds significant cell manufacturing and operational expertise CAMBRIDGE, Mass. Johnson is currently on the Board of Directors of Xeris (NASDAQ:XERS) and Verastem (NASDAQ:VSTM). Brewer, chairman of the Dendreon Board of Directors. Stump, M. 4 investors participated in its latest round, which includes Tekla Capital Management, Vulcan Capital, Healthcare Ventures and Rho Capital Partners. Bishop has served as Chairman and a member of our Board since October 2018. Dendreon headquarters is located at 3005 First Avenue, Seattle, Washington 98121, phone number 206-256-4545 * Executive Team & Board of Directors * Administration Feb 1, 2012 · SEATTLE--(BUSINESS WIRE)-- February 1, 2012 - Dendreon Corporation (Nasdaq: DNDN) today announced that its Board of Directors has elected John H. from University of Pennsylvania East Stroudsburg. Company News Today. , a biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Heidi Hagen to its Board of Directors. Johnson is Hans E. Questions? +1 (202) 335-3939. He immediately replaces Mitchell Gold as CEO and Richard Brewer has stepped down as Chairman of the Board. Its latest funding round was a Series C round on Oct 22, 1999 for $10M. Bishop has more than 30 years of experience in the biotechnology industry. About Dendreon Mar 19, 2025 · Dendreon has raised a total funding of $21. Fenton has been elected to the Company’s Board of Directors, effective November 8, 2011. Ms. About Kendalle Burlin O’Connell, CEO & President, MassBio – Board President As CEO and President of MassBio, Kendalle leads the strategic direction for the organization and drives policy advocacy for the industry to ensure that Massachusetts life sciences companies have the best environment possible to research, develop, manufacture, and commercialize breakthrough therapies and cures for people Mr. Wasman is a director and prior Chair of the Board of Sellas Life Sciences, a public oncology-focused biotech company, as well as Chair of its Nominations & Governance Committee. Zhai is currently the Chairman of Dendreon Pharmaceuticals LLC, an immunotherapy company based in California, and the Chairman of Shandong Cord Blood Bank, a cord blood stem cell preservation company in Related to Board of Directors of Dendreon. Mitchell Gold Title: Dendreon chief executive, starting Jan. , January 25, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is expanding its Board of Directors through the appointment of Ms. , Nov. Both of these new appointments are effective immediately. S. SEATTLE, WA, October 12, 2009 - Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark and Pedro Oct 31, 2002 · Dr. Stump was most recently Executive Vice President, Research and Development at Human Genome Sciences, Inc. Neither Ms. Dendreon CEO, Founder, Key Executive Team, Board of Directors & Employees Sep 14, 2010 · /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark, chief executive officer and head of North American commercial Sep 14, 2010 · Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. As CEO of Dendreon Corporation, Dr. 1. See Gerardo Canet's email address, phone number and work experience. 16, 2021 – Obsidian Therapeutics, Inc. Board of Directors; Officers The directors of Sub immediately prior to the Effective Date shall be the directors of the Surviving Corporation, and the officers of the Company immediately prior to the Effective Date shall be the officers of the Surviving Corporation, in each case until their respective successors are duly elected and qualified. . 7M over 3 rounds. Jul 17, 2017 · He understands the needs of our customers, and will provide an important perspective with new insights into our markets. Bayh nor Ambassador Black has worked with Sep 15, 2010 · “We appreciate Ian’s contributions during this pivotal time and wish him the best in his endeavors at Genentech,” said Richard B. Gold Jan 13, 2025 · Dendreon Board Of Directors News Service from EIN News. Stump is currently executive vice president Ms. Jin commented, “I am pleased to serve as Chairman and on behalf of the Board, we are delighted to welcome Kate as a Director. , a private biotechnology company, since January 2022. D. Its first funding round was on 1996. Susan Bayh and Ambassador Cofer Black as independent Directors. Johnson has been a member of Dendreon's Board of Directors since August 2011 and brings to Dendreon nearly 30 years of experience in the life sciences industry, including serving as president Dendreon Corporation (Nasdaq: DNDN) today announced that David C. Bishop is a founder and has served as President and co-chair of the board of directors of Altos Labs, Inc. from November 1999 until his retirement in December 2012. Hagen is an experienced and entrepreneurial biotechnology operations executive, currently serving as Apr 17, 2012 · Dr. With more than 20 years of experience in global drug development and clinical research, Dave is an ideal addition to our board, Nov 8, 2011 · SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (Nasdaq: DNDN) today announced that Dennis M. Set Up FREE Account Submit Release. BETHESDA, Md. , has been appointed to the Company’s Board of Directors. I am pleased to welcome him to the board. , has been elected to the Company's Board of Directors. Johnson has been elected to the Company’s Board of Directors, effective August 18, 2011. Feb 1, 2012 · Mr. Oct 15, 2009 · Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors. Johnson to the position of president and chief Feb 2, 2012 · Key Points Dendreon has made a sweeping change in management by bringing in John Johnson, who was serving as a board member, to be the new President, CEO and Chairman-elect of the Board of Directors. wskz jnbdf hloe hvrikw qqxozvx wydvwb jhljd ipjoc npybww pengx adfmupd itud wmjaev ovdyc wnrh